Detalhe da pesquisa
1.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Nature
; 585(7823): 107-112, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728218
2.
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
Future Oncol
; 20(15): 959-968, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38390818
3.
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Lancet
; 400(10358): 1117-1129, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099927
4.
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
Future Oncol
; 19(16): 1091-1098, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37309702
5.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Nature
; 547(7662): 222-226, 2017 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28678784
6.
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
J Eur Acad Dermatol Venereol
; 37(5): 894-906, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433688
7.
S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention.
J Dtsch Dermatol Ges
; 21(11): 1422-1433, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37840404
8.
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Nature
; 534(7607): 396-401, 2016 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27281205
9.
Critical Review of the Sentinel Lymph Node Surgery in Malignant Melanoma.
J Drugs Dermatol
; 21(5): 510-516, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35533034
10.
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 848-857, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34000246
11.
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet
; 395(10236): 1558-1568, 2020 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32416781
12.
Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course.
Oncologist
; 26(6): e1058-e1065, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33687742
13.
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis.
BMC Cancer
; 21(1): 1244, 2021 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34798846
14.
Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody-positive autoimmune encephalitis under immune checkpoint inhibitor therapy.
Eur J Neurol
; 28(3): 1086-1089, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33556229
15.
Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients.
J Dtsch Dermatol Ges
; 19(9): 1297-1305, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34357677
16.
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
J Dtsch Dermatol Ges
; 18(6): 582-609, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32489011
17.
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
J Am Acad Dermatol
; 90(2): 414-418, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839734
18.
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018.
J Dtsch Dermatol Ges
; 17(5): 562-576, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31056838
19.
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 19(10): 1315-1327, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30219628
20.
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol
; 19(5): 603-615, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29573941